ViaCyte's implantable stem cell pouch One of CIRM's greatest strengths is supporting projects throughout the development process. Many promising ideas begin in the laboratory. Few advance to human clinical trials. CIRM helps bridge that gap by supporting research from early discovery through clinical testing. A recent announcement from ViaCyte highlights the value of that approach. … Continue reading Producing insulin for people who can’t
PEC-Direct
New partnership to make CIRM supported treatment for type 1 diabetes even better
ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both transplants pancreatic progenitor stem … Continue reading New partnership to make CIRM supported treatment for type 1 diabetes even better